Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “dipeptides”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 811 records · Page 45Linked to original sources
PubMed2003

In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model.

PURPOSE: A dipeptide prodrug of the antiviral nucleoside acyclovir (ACV), val-val-ACV (VVACV), was evaluated in vivo as a potential drug candidate for improving antiviral efficacy against herpetic epithelial and stromal keratitis. METHODS: The effect of 1% VVACV on epithelial keratitis induced by inoculation of HSV-1 strain McKrae (25 microL of 10(5) plaque-forming units [PFU]) in the scarified rabbit cornea and stromal keratitis induced by intrastromal injection of HSV-1 strain RE (10 microL of 10(5) PFU) was compared with that of 1% trifluorothymidine (TFT) and balanced salt solution as the vehicle control. Both eyes of 10 rabbits were used in each treatment group. Lesions were evaluated by slit lamp examinations over a 2-week period after infection. Aqueous humor samples and corneas were analyzed for drug concentrations at the end of each experiment. Cytotoxicity of VVACV in comparison with val-acyclovir (VACV), ACV, and TFT was evaluated in cellular proliferation assays. RESULTS: The dipeptide prodrug VVACV demonstrated excellent activity against HSV-1 in the rabbit epithelial and stromal keratitis models: 1% VVACV was as effective as 1% TFT. The prodrug was also less cytotoxic than TFT, which is the only effective drug currently licensed and routinely used for topical treatment of ocular herpes infections in the United States. CONCLUSIONS: The less cytotoxic and highly water-soluble prodrug VVACV, which showed excellent in vivo activity against HSV-1 in rabbit epithelial and stromal keratitis, is a promising drug candidate for treatment of ocular HSV infections.

Acyclovir↗
PubMed2000

Aerosol delivery of muramyl dipeptide to rodent lungs.

Tuberculosis is the single most serious infectious disease worldwide. The respiratory tract is the primary site of infection by Mycobacterium tuberculosis(MTB). A number of immunogenic components of the cell wall of MTB, if delivered to the lungs as aerosols, can be used to study the local immune response. The site of deposition of these aerosols can be employed to control their residence time in the lungs. Muramyl dipeptide (MDP) aerosols were delivered to alveolar macrophages in the lungs of rodents. Guinea pig macrophages harvested by bronchoalveolar lavage were examined by differential interference contrast microscopy for morphological changes indicative of activation. Bronchoalveolar lavage fluid was analyzed for the presence of alkaline phosphatase, lactate dehydrogenase, N-acetyl-glucosaminidase (NAG), and total protein content. Rat alveolar macrophages were studied for the production of nitric oxide, by induction of nitric oxide synthase. Twenty-four hours following exposure to an aerosol of MDP, alveolar macrophages exhibited morphological characteristics (spreading and pseudopodia), enzyme activity (NAG 50% above control), and production of the reactive intermediate nitric oxide. Rat macrophages subjected to aerosol exposure to MDP when challenged with a second dose of MDP or lipopolysaccharide exhibited a linear dose response as measured by nitric oxide production. These studies indicate that the topical delivery of an MTB bacterial cell wall component, muramyl dipeptide, results in activation of alveolar macrophages. This approach may be useful in elucidating elements of the immune response to MTB.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1991

The nephritogenic glycopeptide from rat glomerular basement membrane. X. Synthesis of an N-triglycosyl dipeptide and characteristics of its cis-trans isomers.

Isomers of O-alpha-D-glucopyranosyl-(1----6)-O-beta-D-glucopyranosyl- (1----6)-N-[L-aspart-1-oyl-(L-proline)-4-oyl]-alpha-D-glucopyranos ylamine have been prepared, as models for a derivative possibly present in the glomerular basement membrane of rats, by condensation of the corresponding dipeptide derivative (5) with triglycosylamine (4) in the presence of O,O-diethylcyanophosphonate, followed by deprotection of the trisaccharide-dipeptide derivative. During the deprotection process, cis- and trans-isomers containing proline were separated by silica gel column chromatography and also reversed-phase high performance liquid chromatography.

Amino Acid Sequence↗
PubMed2001

Boronated dipeptide borotrimethylglycylphenylalanine as a potential boron carrier in boron neutron capture therapy for malignant brain tumors.

Takagaki, M., Ono, K., Masunaga, S-I., Kinashi, Y., Oda, Y., Miyatake, S-I., Hashimoto, N., Powell, W., Sood, A. and Spielvogel, B. F. Boronated Dipeptide Borotrimethylglycylphenylalanine as a Potential Boron Carrier in Boron Neutron Capture Therapy for Malignant Brain Tumors. Radiat. Res. 156, 118-122 (2001).A boronated dipeptide, borotrimethylglycylphenylalanine (BGPA), was synthesized as a possible boron carrier for boron neutron capture therapy (BNCT) for malignant brain tumors. In vitro, at equal concentrations of (10)B in the extracellular medium, BGPA had the same effect in BNCT as p-boronophenylalanine (BPA). Boron analysis was carried out using prompt gamma-ray spectrometry and track-etch autoradiography. The tumor:blood and tumor:normal brain (10)B concentration ratios were 8.9 +/- 2.1 and 3.0 +/- 1.2, respectively, in rats bearing intracranial C6 gliosarcomas using alpha-particle track autoradiography. The IC(50), i.e. the dose capable of inhibiting the growth of C6 gliosarcoma cells by 50% after 3 days of incubation, was 5.9 x 10(-3) M BGPA, which is similar to that of 6.4 x 10(-3) M for BPA. The amide bond of BGPA is free from enzymatic attack, since it is protected from hydrolysis by the presence of a boron atom at the alpha-carbon position of glycine. These results suggest promise for the use of this agent for BNCT of malignant brain tumors. Further preclinical studies of BGPA are warranted, since BGPA has advantages over both BPA and BSH.

Alanine↗
PubMed2002

Presence of distinct virtual backbone torsion angles in dipeptide conformers.

Zwitterionic dipeptides have recently been shown to exist in water mainly as nine conformational forms with specific combinations of backbone Psi, omega and Phi torsions, which allows conformer-specific molecular recognition of peptide ligands by proteins. Here, we show that pairs of virtual backbone torsions can also define these nine conformational forms, and that comparing these virtual torsions in dipeptides with those of backbone-modified pseudopeptides offers an improved procedure for evaluating peptidomimetics for therapeutic applications.

Calorimetry↗
PubMed1999

[Formation of dipeptides--a side reaction in racemization of phenylalanine].

It was shown that acetylated dipeptides, Ac-D-Phe-D-Phe-OH, Ac-L-Phe-L-Phe-OH, Ac-D-Phe-L-Phe-OH, and Ac-L-Phe-D-Phe-OH, are formed during D-phenylalanine racemization. The overall content of these dipeptides in the reaction mixture ranged from 40 to 60% depending on the reaction conditions. We concluded that, like alpha-aminoisobutyric acid, phenylalanine is prone to polymerization under racemization conditions.

Chromatography, High Pressure Liquid↗
PubMed1992

[An increase in the immunogenicity of bacterial antigens under the influence of one of the derivatives of muramyl dipeptide].

As revealed in animal experiments, glucosaminylmuramyl dipeptide (GMDP), the synthetic analog of muramyl dipeptide, when introduced intraperitoneally in a single injection or orally, exhibits adjuvant activity with respect to Citrobacter 0-antigens, Shigella flexneri and enhances the protective properties of dysentery and pertussis vaccines. The stimulating properties of GMDP depend on its dose, the route of its administration, the time elapsed after its administration, its ratio to the concomitant doses of bacterial antigens and to the dose of the virulent culture used for challenge.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1986

[Effect of derivatives of substance P dipeptide on nerve fiber growth in tissue culture].

Explants and cells from the peripheral (PNS) and central nervous system (CNS) were cultivated in MAXIMOW chambers. The following four derivatives of Substances P (SP) dipeptide were tested for their effects in concentrations between 10(-4) and 10(-8) mol/l: Lys-Pro X 2HBr, Lys(Z)-Pro X HCl, Lys[Z(NO2)]-Pro X HCl and cyclo(Lys-Pro) X HCl. The results suggest that SP and SP derivatives may modulate nerve fibre outgrowth in vitro. In ganglion trigeminale explants Lys(Z)-Pro X HCl stimulated the growth of nerve fibres. The explant covered areas increased significantly. In telencephalon explants and cell cultures the tested derivatives did not essentially promote neurite outgrowth. In retinal cell cultures incubated with cyclo(Lys-Pro) X HCl and Lys[Z(NO2)]-Pro X HCl the neurite outgrowth index was stimulated in a different way. The neurite length was affected and stimulated in the presence of Lys(Z)-Pro X HCl and cyclo(Lys-Pro) X HCl. Both for survival and differentiation PNS neurons depend on specific biofactors. In sensory ganglia explants SP and especially SP derivatives were shown to improve neuronal survival provided that serum or embryonic extract was simultaneously present in the medium. Even if the dipeptides need other biofactors for their full function the may be discussed as neuronotrophic factors because they ensure survival and general growth capability of the responsive neuroblasts.

Animals↗
PubMed1986

Anticonflict properties of the dipeptide Litoralon and of diazepam in rats.

The anticonflict properties of the anxiolytic diazepam and of the dipeptide Litoralon gamma-L-glutamyl-taurine and two of its analogues SZJ 3388, gamma-aminobutyryl-ethanolamine phosphate, and SZJ 3361, D-1-aminoisobutyrylethanolamine phosphate have been investigated in a "time-to-emerge" conflict paradigm in non-deprived rats. Diazepam, Litoralon and compound SZJ 3388 significantly decreased the "time-to-emerge" latency (TTE latency) in a dose-dependent manner versus saline- or vehicle-treated controls in doses between 0.05 and 0.50 mg/kg intraperitoneally. The analogue SZJ 3361 was inactive as regards the TTE latency, while the anti-histaminic promethazine lengthened the TTE latency in a dose-dependent manner. The number of irresolute responses was significantly decreased following administration of diazepam, SZJ 3388 and Litoralon and was positively correlated with the TEE latency-decreasing activity of these compounds. The data are discussed in terms of the benzodiazepine-like anxiolytic or anti-conflict properties of these dipeptides.

Animals↗
PubMed1989

Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative.

The ability of liposomes containing a synthetic lipophilic muramyl dipeptide derivative, N-acetylmuramyl-L-alanyl-D-isoglutamyl-sn-glycerol dipalmitate (MDP-GDP), to inhibit the growth of experimental B16-F1 melanoma liver metastases in syngeneic C57BL/6 mice has been determined. Multiple i.v. injections of distearoylphosphatidylcholine:dimyristoylphosphatidylglycerol liposomes (1 mumol, 10:1 molar ratio) containing 0.1 to 1 microgram of MDP-GDP given at 3- to 4-day intervals after seeding the livers with tumor cells resulted in a significant inhibition of the number of experimental B16 liver metastases. Control liposomes or free MDP (100 micrograms) failed to affect the number of experimental metastases. A single prophylactic injection of liposomes containing MDP-GDP was equally effective in eliciting a reduction in the number of experimental liver metastases. The ability of liposomal MDP-GDP to inhibit the growth of liver metastases correlated with its ability to induce Kupffer cell tumoricidal activity against the tumor cell targets; activation of C57BL/6 Kupffer cell activity in vitro was most effective with liposomal MDP-GDP, followed by liposomal MDP and free MDP. Only liposomal MDP-GDP and liposomal MDP were able to induce Kupffer cell tumoricidal activity in situ, free MDP being inactive. Liposomal muramyl dipeptide therapy using lipophilic derivatives would appear to be an effective treatment for hepatic metastases derived from primary tumors.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1986

The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction.

The purpose of this study was to identify the mechanism by which muramyl dipeptide (MDP) activates antitumor cytotoxic properties in normal and interferon-gamma (IFN-gamma)-primed human peripheral blood monocytes. The structurally and functionally active MDP analog, nor-muramyl dipeptide (nor-MDP), and [3H]nor-MDP were used as reference glycopeptides. Direct activation of normal, noncytotoxic monocytes by nor-MDP was enhanced by its encapsulation within multilamellar vesicles (MLV). Studies with [3H]nor-MDP revealed that the activation of monocytes by nor-MDP was not attributable to its interaction with a specific cell surface receptor, nor did it result merely from the internalization by monocytes of glycopeptide. Subthreshold concentrations of nor-MDP could activate tumor cytotoxic properties in IFN-gamma-primed monocytes. The intracellular interaction of [3H]nor-MDP with IFN-gamma-primed monocytes was specific in that intracellular levels of radiolabeled material could be displaced and recovered as intact molecules by unlabeled nor-MDP, but not by a biologically inactive MDP stereoisomer. Collectively, these results suggest that the activation of tumoricidal properties in human blood monocytes by MDP occurs subsequent to intracellular interaction with specific MDP receptors.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1986

Effects of muramyl dipeptide and lead acetate on carbon clearance and endotoxin-induced mortality in mice.

Muramyl dipeptide (MDP) is a nonspecific immune adjuvant thought to affect the macrophage. MDP had been used safely without immunosuppressive or toxic side effects in our laboratory and others. Endotoxin, or lipopolysaccharide (LPS), is thought to be responsible for many of the systemic toxic effects of gram-negative infection. Lead acetate potentiates the lethal effects of endotoxin, an effect attributed to increased hepatotoxicity involving both hepatocytes and Kupffer macrophages. This study was undertaken to examine putative mechanism of action of MDP relating to the reticuloendothelial system. Endotoxin was given intraperitoneally to susceptible mice that were pretreated with MDP, lead acetate, or both, and to unmodified controls. Lead acetate significantly enhanced lethality due to LPS, but pretreatment with MDP did not alter mortality. Carbon clearance was measured in mice treated with MDP, lead, or both. There was no difference in the phagocytic index of control mice and those mice treated with lead acetate at various times prior to the injection. Carbon clearance increased significantly in mice pretreated with MDP but was unaltered by the addition of lead acetate. We conclude that if hyperphagocytosis of endotoxin occurs in MDP-pretreated mice, it does not cause additional mortality. Muramyl dipeptide appeared to be a safe reticuloendothelial stimulant that did not enhance the toxicity of lead or LPS in this experimental model.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1987

Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.

The purpose of these studies was to determine whether the oral administration of a lipophilic analog of muramyl dipeptide, MTP-PE, can produce in situ activation of tumoricidal properties in mouse macrophages. MTP-PE was dissolved in a phosphate-buffered saline to produce micelles. Single or multiple oral administrations of MTP-PE produced tumoricidal activation in both lung and peritoneal macrophages. This was in direct contrast to the i.v. or i.p. administrations of MTP-PE incorporated in liposomes, which produced activation in only lung or only peritoneal macrophages, respectively. The distribution and fate of [3H]-labeled MTP-PE subsequent to oral administration revealed that MTP-PE was found in various organs independent of reticuloendothelial activity. Finally, the repeated twice-weekly oral administrations of MTP-PE inhibited lung and lymph node metastasis in C57BL/6 mice by syngeneic B16 melanoma cells. The oral administration of MTP-PE, however, was not effective in eradicating well-established melanoma metastases. We conclude that the oral administration of a lipophilic muramyl dipeptide produces systemic activation of macrophages. The feasibility of enhancing host defense against infections and cancer by the oral administration of an immunomodulator has obvious clinical advantages.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1985

Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.

The ability of a member of a new class of lipophilic muramyl dipeptide (MDP) derivative, muramyl dipeptide-glyceryldipalmitate (MDP-GDP), to induce alveolar macrophage cytotoxic activity in vitro towards B16 melanoma cells when incorporated into two types of liposome was studied. MDP-GDP incorporated into conventionally prepared liposomes formulated from distearoylphosphatidylcholine and phosphatidylserine (7:3 molar ratio) was 10-fold more effective than liposomes containing MDP, and 7000-fold more effective than free MDP in inducing macrophage cytotoxic activity. MDP-GDP incorporated into freeze-dried liposomes was 50,000- to 100,000-fold more effective than free MDP in inducing such activity. Freeze-dried liposomes containing MDP-GDP were efficiently localized in the lungs of normal mice, and induced cytotoxic activity in the alveolar macrophages. Such liposomes were able to significantly reduce the pulmonary metastatic burden of mice carrying the B16 melanoma. These data provide evidence that this class of lipophilic MDP derivative, when incorporated into freeze-dried liposomes, is a potent inducer of macrophage cytotoxic activity in vitro and in situ, and has antitumor activity in vivo. In addition, the use of a freeze-drying procedure allows the preparation and long-term storage of reproducible liposome formulations.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1985

[Use of muramyl dipeptides in models of synthetic vaccines].

Vaccination represents a great success in clinical immunology and new approaches for designing vaccines of the future are now available. Protective antigens could be obtained by recombinant DNA technology or by synthesis. These new immunogens are likely to be poor immunogens and require the use of carrier and adjuvants. Both carrier and adjuvant present some limitations. In this report we consider how synthetic glycopeptides analogous to muramyl dipeptide (MDP) can be used as adjuvants under suitable conditions and can also overcome some problems due to the carrier. Muramyl dipeptides and chiefly Murabutide (NAcMur-L-Ala-D-Gln-alpha-n-butyl-ester) which is a derivative currently undergoing clinical trials can enhance the immune response to conventional purified vaccines. They can be also used in synthetic vaccines. In this case they are more active when covalently linked to the immunogen. Several examples of semisynthetic monovalent and polyvalent vaccines (Streptococcus, diphtheria toxin, Hepatitis B, Plasmodium) are described as well as totally synthetic vaccines (LH-RH, Foot-and-Mouth disease virus). They demonstrate that by using Murabutide biologically active antibodies can be produced under conditions applicable to human use.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1985

Muramyl dipeptide enhances in vitro peritoneal macrophage phagocytic activity.

There is little agreement as to the precise mechanism of action of muramyl dipeptide (MDP) despite a steadily unfolding series of experiments designed for clarification. This report further defines the role of MDP in nonspecific enhancement of host defenses by examining its effect on in vitro macrophage phagocytosis. Peritoneal macrophages were incubated in vitro with muramyl dipeptide. Phagocytic indices were determined using the iodination technique. The macrophages treated with MDP had a significant increase in their phagocytic function compared to control cells, adding to the understanding of the mechanism of action of MDP and raising the possibility of a trial peritonitis in humans.

Acetylmuramyl-Alanyl-Isoglutamine↗
PubMed1978

Stimulation of an enhanced in vitro immune response by a synthetic adjuvant, muramyl dipeptide.

Various subcellular bacterial fractions are known to enhance immune responses and serve as potent adjuvants. Muramyl dipeptide (MDP), a synthetic adjuvant mimicking a component of mycobacterial cell walls, enhances humoral immunity to soluble antigens and can increase macrophage cytotoxicity toward mastocytoma cells in vitro. In the present study MDP was found to enhance the hemolytic antibody plaque response of normal mouse spleen cells in vitro to SRBC at a level equal to or greater than that induced by Escherichia coli lipopolysaccharide. Furthermore, MDP was found to enhance the antibody response to SRBC nonspecifically in unimmunized spleen cell cultures, suggesting that similar to LPS the synthetic dipeptide may induce a generalized clonal expansion of committed lymphocytes and thus serve as a "polyclonal activator." MDP also enhanced the immune responsiveness of normal splenocytes to suboptimum concentrations of SRBC, indicating that this material may be useful in enhancing immunity in situations where there would normally be a poor immune response.

Adjuvants, Immunologic↗
PubMed1984

The role of muramyl dipeptide in the therapy of established experimental bacterial infection.

Muramyl dipeptide (MDP) actively potentiates host defences and confers protection when given before a bacterial challenge. Experiments were undertaken to characterize its actions when used alone or in combination with cephaloridine in a manner analogous to clinical therapy, i.e. after initiation of bacterial infection. MDP, alone or in combination, significantly decreased the systemic manifestations of infection compared with placebo when administered up to 6 h following bacterial contamination. Its effect on the primary lesion was less marked, but it may potentiate host defences sufficiently to have an impact on the decisive period. Benefits observed in this study were of lesser magnitude than those observed following administration of the dipeptide before bacterial inoculation.

Acetylmuramyl-Alanyl-Isoglutamine↗